{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:19:40Z","timestamp":1789017580166,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adolescent and young adult patients with acute lymphoblastic leukemia (ALL) have superior outcomes when treated on pediatric regimens. Pediatric ALL regimens rely heavily on corticosteroids and asparaginase and are known to increase the risk of osteonecrosis (ON) and fractures in children, particularly adolescents. Orthopedic toxicity among young adults treated on pediatric-inspired regimens is not well described. Here, we report the symptomatic orthopedic toxicities of patients aged 15 to 50 years treated on sequential Dana-Farber Cancer Institute ALL Consortium protocols. Among 367 patients with a median age of 23 years (range, 15-50 years; 68% aged &amp;lt;30 years), 60 patients were diagnosed with ON (5-year cumulative incidence, 17%; 95% confidence interval [CI], 13-22), and 40 patients experienced fracture (5-year cumulative incidence, 12%; 95% CI, 8-15). Patients aged &amp;lt;30 years were significantly more likely to be diagnosed with ON (5-year cumulative incidence, 21% vs 8%; P = .004). Patients treated more recently on pegaspargase-based protocols were significantly more likely to be diagnosed with ON compared with those treated on earlier trials with native Escherichia coli asparaginase (5-year cumulative incidence, 24% vs 5%; P &amp;lt; .001). Of the 54 ON events for which adequate information was available, surgery was performed in 25 (46%). Patients with ON had superior overall survival (OS) compared with those without (multivariable OS hazard ratio, 0.15; 95% CI, 0.05-0.46; P = .001; ON included as a time-varying exposure). Increased rates of orthopedic toxicity in late-generation protocols may be driven by the pharmacokinetic drug interaction between pegaspargase and dexamethasone, leading to higher dexamethasone exposure.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005278","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T01:51:56Z","timestamp":1633485116000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Data Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-4213","authenticated-orcid":false,"given":"Andrew E.","family":"Place","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda M.","family":"Vrooman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-7894","authenticated-orcid":false,"given":"Giacomo","family":"Gotti","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nauffal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan-Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"issue":"5","key":"2021123016210069200_B1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"2021123016210069200_B2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2021123016210069200_B3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021123016210069200_B4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.22189","article-title":"Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol","volume":"107","author":"Hallb\u00f6\u00f6k","year":"2006","journal-title":"Cancer."},{"issue":"10","key":"2021123016210069200_B5","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J."},{"issue":"21","key":"2021123016210069200_B6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults with acute lymphoblastic leukemia: early results of U.S. Intergroup trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood."},{"issue":"3","key":"2021123016210069200_B7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia."},{"issue":"6","key":"2021123016210069200_B8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009;27(15):2574]","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol."},{"issue":"20","key":"2021123016210069200_B9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021123016210069200_B10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021123016210069200_B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2016","journal-title":"Eur J Haematol."},{"issue":"18","key":"2021123016210069200_B12","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","article-title":"Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children\u2019s Cancer Group","volume":"18","author":"Mattano","year":"2000","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021123016210069200_B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"Mattano","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"2021123016210069200_B14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","article-title":"High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis","volume":"22","author":"Patel","year":"2008","journal-title":"Leukemia."},{"issue":"2","key":"2021123016210069200_B15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/bloodadvances.2020003060","article-title":"Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort","volume":"5","author":"Yao","year":"2021","journal-title":"Blood Adv."},{"issue":"12","key":"2021123016210069200_B16","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv."},{"issue":"11","key":"2021123016210069200_B17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V110.11.587.587","article-title":"A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia","volume":"110","author":"DeAngelo","year":"2015","journal-title":"Blood."},{"issue":"5","key":"2021123016210069200_B18","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood."},{"issue":"2","key":"2021123016210069200_B19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv."},{"issue":"11","key":"2021123016210069200_B20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3324\/haematol.2016.147595","article-title":"Osteonecrosis in children with acute lymphoblastic leukemia","volume":"101","author":"Kunstreich","year":"2016","journal-title":"Haematologica."},{"issue":"12","key":"2021123016210069200_B21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2006.06.2539","article-title":"High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia","volume":"25","author":"Niinim\u00e4ki","year":"2007","journal-title":"J Clin Oncol."},{"issue":"16","key":"2021123016210069200_B22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4-5","key":"2021123016210069200_B23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.thromres.2003.10.007","article-title":"Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy","volume":"111","author":"Athale","year":"2003","journal-title":"Thromb Res."},{"issue":"3","key":"2021123016210069200_B24","doi-asserted-by":"crossref","first-page":"e0151433","DOI":"10.1371\/journal.pone.0151433","article-title":"Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One."},{"issue":"8","key":"2021123016210069200_B25","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3324\/haematol.2020.252767","article-title":"Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice","volume":"106","author":"Finch","year":"2021","journal-title":"Haematologica."},{"issue":"5","key":"2021123016210069200_B26","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3324\/haematol.2016.160507","article-title":"Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia","volume":"102","author":"Mogensen","year":"2017","journal-title":"Haematologica."},{"issue":"12","key":"2021123016210069200_B27","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1200\/JCO.2007.13.8404","article-title":"Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia","volume":"26","author":"Yang","year":"2008","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021123016210069200_B28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/clpt.2009.162","article-title":"Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia","volume":"86","author":"Panetta","year":"2009","journal-title":"Clin Pharmacol Ther."},{"issue":"34","key":"2021123016210069200_B29","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children\u2019s Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021123016210069200_B30","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1111\/bjh.16589","article-title":"Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia","volume":"189","author":"Inaba","year":"2020","journal-title":"Br J Haematol."},{"key":"2021123016210069200_B31","author":"National Comprehensive Cancer Network","year":"2021"},{"issue":"1","key":"2021123016210069200_B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41397-017-0002-4","article-title":"Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia","volume":"19","author":"Plesa","year":"2019","journal-title":"Pharmacogenomics J."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/72\/1856144\/advancesadv2021005278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/72\/1856144\/advancesadv2021005278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T16:23:45Z","timestamp":1640881425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/1\/72\/477173\/Orthopedic-toxicities-among-adolescents-and-young"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005278","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]}}}